Table of contents
Expand All Topics
Non-gonococcal urethritis
Guidelines
Key sources
The following summarized guidelines for the evaluation and management of non-gonococcal urethritis are prepared by our editorial team based on guidelines from the World Health Organization (WHO 2024), the Center for Disease Control (CDC 2021), the Japanese Association for Infectious Disease (JAID/JSC 2021), the British Association for Sexual Health and HIV (BASHH 2018), and the International Union Against Sexually Transmitted ...
Show more
Screening and diagnosis
Diagnosis
As per IUSTI 2016 guidelines:
Confirm urethritis by demonstrating polymorphonuclear leukocytes from the anterior urethra using a Gram or methylene-blue stained urethral smear, which should contain 5 polymorphonuclear leukocytes/hpf (averaged over 5 fields with the greatest concentration of polymorphonuclear leukocytes).
⁄
Consider diagnosing urethritis based on the following criteria if microscopy is not available:
presence of a mucopurulent or purulent urethral discharge on examination
≥ 1+ on a leukocyte esterase dipstick in a first void urine specimen
threads in a first void urine specimen (threads may be physiological, such as semen)
C
Classification and risk stratification
Diagnostic investigations
Indication for testing: as per IUSTI 2016 guidelines, evaluate for urethritis in patients with symptoms or visible discharge.
B
Show 2 more
More topics in this section
First void urine
Urethral smear
Vaginal smear
Antimicrobial susceptibility testing
Assessment of sexual partners
Medical management
General principles: as per WHO 2024 guidelines, decide on the choice of therapy for Mycoplasma genitalium infection based on an individual resistance profile, surveillance data, or suspected resistance from typical prescribing practices (antibiotic consumption) for other infections.
A
More topics in this section
First-line therapy
Second-line therapy
Patient education
Follow-up and surveillance
Follow-up testing: as per BASHH 2018 guidelines, obtain a test of cure in all patients 5 weeks after the start of treatment (and no sooner than 3 weeks to avoid false negative results) to ensure microbiological cure and to help identify emerging resistance.
B
More topics in this section
Evaluation of persistent/recurrent disease
Management of persistent/recurrent disease